Profound tumor-specific Th2 bias in patients with malignant glioma.
about
PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.
P2860
Profound tumor-specific Th2 bias in patients with malignant glioma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Profound tumor-specific Th2 bias in patients with malignant glioma.
@ast
Profound tumor-specific Th2 bias in patients with malignant glioma.
@en
Profound tumor-specific Th2 bias in patients with malignant glioma.
@nl
type
label
Profound tumor-specific Th2 bias in patients with malignant glioma.
@ast
Profound tumor-specific Th2 bias in patients with malignant glioma.
@en
Profound tumor-specific Th2 bias in patients with malignant glioma.
@nl
prefLabel
Profound tumor-specific Th2 bias in patients with malignant glioma.
@ast
Profound tumor-specific Th2 bias in patients with malignant glioma.
@en
Profound tumor-specific Th2 bias in patients with malignant glioma.
@nl
P2093
P2860
P356
P1433
P1476
Profound tumor-specific Th2 bias in patients with malignant glioma.
@en
P2093
David E Anderson
Jeffrey N Bruce
Lisa M Maier
Richard C E Anderson
Richard Maier
Shinji Shimato
P2860
P2888
P356
10.1186/1471-2407-12-561
P407
P577
2012-11-27T00:00:00Z
P5875
P6179
1043552797